Research programme: growth factor modulators - Scholar Rock

Drug Profile

Research programme: growth factor modulators - Scholar Rock

Alternative Names: Niche modulators - Scholar Rock; SRK 015

Latest Information Update: 12 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Scholar Rock
  • Class Antifibrotics
  • Mechanism of Action Myostatin inhibitors; TGF-beta superfamily protein inhibitors; TGF-beta superfamily protein-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Fibrosis; Musculoskeletal disorders; Spinal cord injuries; Spinal muscular atrophy

Most Recent Events

  • 12 Jul 2017 Preclinical trials in Spinal cord injuries in USA (unspecified route) before July 2017
  • 10 Jul 2017 Preclinical trials in Spinal muscular atrophy in USA (unspecified route)
  • 10 Jul 2017 Pharmacodynamics data from a preclinical study in Spinal cord injury released by Scholar Rock
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top